Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Neutral 56.6%

Neg 0% Neu 56.6% Pos 0%

Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $16 to $14.